Physician profile
Liam D Donovan
NPI 1083452502
$4,676.74
in general payments reported to CMS, 2019-2025
21 companies · $3,548 in 2025
The $3,548 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,129 · 2025: $3,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.16 |
| Education | $185.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $811.31 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $602.05 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $480.69 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $446.78 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $441.36 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $279.60 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $210.59 | 2024-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $209.68 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $178.25 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $168.68 | 2024-2025 | |
| Almatica Pharma LLC | $111.66 | 2024-2025 | Loreev Xr |
| Luye Pharma (USA) LTD. | $107.55 | 2025 | Erzofri Extended-Release |
| Collegium Pharmaceutical, INC. | $105.95 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $105.47 | 2024-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $101.31 | 2024-2025 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $84.47 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $70.12 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $66.80 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $49.28 | 2025 | Qelbree |
| Tempus Ai, INC | $29.13 | 2024 | Tempus Pixel |
| Tms Neurohealth Centers INC. | $16.01 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liam Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.